Renascience Inc. (4889) Stock Price

Rena Science develops pharmaceuticals, medical devices, and AI-powered software as a medical device (SaMD) by leveraging diverse modalities to address challenges in clinical settings. The company aims to create medical innovations and enable people to enjoy better physical and mental health through new healthcare solutions.

The company tackles socially important medical issues, including age-related diseases accompanying Japan's declining birthrate and aging population, as well as diseases affecting women and children. It has development programs targeting cancer, diabetes, respiratory diseases, and cardiovascular diseases, advancing research and development of treatments for these conditions.

Rena Science diversifies its drug development modalities from small-molecule pharmaceuticals to biologics. The company also focuses on developing AI-powered SaMD to expand treatment options in clinical practice. It incorporates engineering and information technology expertise to explore new medical solutions.

The company collaborates with universities and research institutions domestically and internationally, conducting integrated research from basic science through clinical development. It contributes to medical innovation through licensing agreements with major pharmaceutical companies. For example, in developing ultra-thin endoscopes, the company jointly advanced product concept development, prototype creation, non-clinical testing, and investigator-initiated clinical trials with multiple universities.

Rena Science prioritizes investigator-initiated clinical trials and conducts integrated development from basic research through clinical trials to achieve efficient development. This approach enables the company to develop treatments for rare diseases and generate business revenue in areas where major pharmaceutical companies have limited focus.

The company promotes open innovation and leverages alliances with external organizations for efficient development. It has established open innovation laboratories at Tohoku University and Hiroshima University to enhance research and development efficiency and accelerate business growth.

Rena Science's business model involves developing proprietary products and utilizing external research seeds from universities, validating therapeutic concepts through investigator-initiated clinical trials, and licensing out to pharmaceutical companies. The company generates revenue through upfront payments, milestone payments, royalty income, and collaborative or contract research fees.

The company operates as a single business segment engaged in the development and commercialization of pharmaceuticals and medical devices. Business revenue comprises upfront payments, milestone payments, royalty income, collaborative research income, and contract research income.

Rena Science develops pharmaceuticals, medical devices, and AI-powered software as a medical device (SaMD) by leveraging diverse modalities to address challenges in clinical settings. The company aims to create medical innovations and enable people to enjoy better physical and mental health through new healthcare solutions.

The company addresses socially important medical challenges, including age-related diseases accompanying Japan's declining birthrate and aging population, as well as diseases affecting women and children. It maintains development programs targeting cancer, diabetes, respiratory diseases, and cardiovascular diseases, advancing research and development of treatments for these conditions.

Rena Science diversifies its drug development modalities from small-molecule pharmaceuticals to biopharmaceuticals. The company also focuses on developing AI-powered SaMD to expand treatment options in clinical practice. It incorporates engineering and information technology expertise to explore new medical solutions.

The company collaborates with universities and research institutions domestically and internationally, conducting integrated research from basic science through clinical development. It contributes to medical innovation through licensing agreements with major pharmaceutical companies. For example, in developing ultra-thin endoscopes, the company jointly advanced product concept development, prototype creation, non-clinical testing, and physician-initiated clinical trials with multiple universities.

Rena Science prioritizes physician-initiated clinical trials and conducts integrated development from basic research through clinical trials to achieve efficient development. This approach enables the company to develop treatments for rare diseases and generate business revenue in areas where major pharmaceutical companies have limited focus.

The company promotes open innovation and leverages alliances with external organizations for efficient development. It has established open innovation laboratories at Tohoku University and Hiroshima University to enhance research and development efficiency and accelerate business growth.

Rena Science's business model combines internally developed products with external research seeds from universities. The company validates therapeutic concepts through physician-initiated clinical trials and licenses them to pharmaceutical companies. This generates revenue through upfront payments, milestone payments, and royalty income.

The company operates as a single business segment engaged in the development and commercialization of pharmaceuticals and medical devices. Business revenue comprises upfront payments, milestone payments, royalty income, and collaborative and contract research income.